NextCure Inc. Overview
NextCure, Inc. is a clinical-stage biopharmaceutical company specializing in the development of immunomedicines for cancer and other diseases. Operating from its headquarters in Beltsville, Maryland, the company is a key player in the health care sector. Investors and stakeholders can track its performance on the Nasdaq stock exchange, where its stocks are actively traded.
Recent Stock Performance
Over the past year, NextCure’s stock has experienced significant volatility. The stock reached a 52-week high of $1.82 USD on July 15, 2024, and a low of $0.224 USD on April 9, 2025. As of the latest data, the stock closed at $0.508 USD on May 26, 2025. This fluctuation highlights the dynamic nature of the biopharmaceutical market and the challenges faced by companies in this sector.
Valuation Metrics
The company’s valuation metrics present a complex picture. With a price-to-earnings (P/E) ratio of -0.280946, NextCure is currently not generating positive earnings, which is not uncommon for clinical-stage biopharmaceutical companies. The price-to-book (P/B) ratio stands at 0.24925, further indicating that the market valuation is below the book value of the company’s assets. These metrics suggest that investors may need to conduct a deeper analysis to fully understand the company’s financial health and future potential.
Market Capitalization
NextCure’s market capitalization is currently valued at $13,940,000 USD. This figure reflects the total market value of the company’s outstanding shares and provides insight into its size and scale within the biopharmaceutical industry.
Conclusion
NextCure, Inc. remains focused on its mission to develop innovative immunomedicines for cancer and other diseases. Despite the challenges reflected in its stock performance and valuation metrics, the company continues to operate within the competitive health care sector. For more detailed information on its activities and offerings, stakeholders are encouraged to visit the company’s website at www.nextcure.com .